Chris Shibutani
Stock Analyst at Goldman Sachs
(2.84)
# 1,895
Out of 5,091 analysts
96
Total ratings
54%
Success rate
5.6%
Average return
Main Sectors:
Stocks Rated by Chris Shibutani
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PCVX Vaxcyte | Maintains: Buy | $138 → $100 | $46.18 | +116.54% | 2 | Apr 1, 2025 | |
| ERAS Erasca | Maintains: Buy | $3.5 → $3 | $3.34 | -10.18% | 7 | Mar 21, 2025 | |
| MCRB Seres Therapeutics | Maintains: Sell | $20 → $15 | $17.18 | -12.69% | 4 | Mar 14, 2025 | |
| ALKS Alkermes | Maintains: Buy | $30 → $32 | $29.41 | +8.81% | 7 | Feb 14, 2025 | |
| BNTX BioNTech SE | Upgrades: Buy | $90 → $137 | $97.28 | +40.83% | 7 | Nov 8, 2024 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $30 → $33 | $19.98 | +65.17% | 3 | Nov 7, 2024 | |
| UTHR United Therapeutics | Maintains: Neutral | $243 → $302 | $479.51 | -37.02% | 4 | Nov 1, 2024 | |
| RPRX Royalty Pharma | Maintains: Buy | $50 → $51 | $38.67 | +31.89% | 3 | Aug 14, 2024 | |
| JNJ Johnson & Johnson | Maintains: Neutral | $160 → $155 | $201.62 | -23.12% | 3 | Jul 19, 2024 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Neutral | $3 → $4 | $13.67 | -70.74% | 8 | Jul 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $20 | $7.29 | +174.35% | 5 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $650 → $723 | $997.59 | -27.53% | 6 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $29 → $26 | $17.76 | +46.40% | 1 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $134 → $153 | $154.99 | -1.28% | 2 | Jan 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $173 | $223.12 | -22.46% | 4 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $57.28 | - | 4 | Nov 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $81 → $69 | $51.67 | +33.54% | 5 | Oct 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $13 | $21.00 | -38.10% | 2 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $20 → $23 | $80.06 | -71.27% | 3 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $8.80 | +468.18% | 1 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $52 | $94.30 | -44.86% | 2 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $47 → $60 | $25.77 | +132.83% | 2 | Dec 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $18 | $11.04 | +63.04% | 4 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $17 | $9.60 | +77.08% | 1 | Sep 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $2.15 | - | 1 | Jul 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $5.88 | - | 1 | Feb 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $5.40 | - | 4 | Jan 24, 2018 |
Vaxcyte
Apr 1, 2025
Maintains: Buy
Price Target: $138 → $100
Current: $46.18
Upside: +116.54%
Erasca
Mar 21, 2025
Maintains: Buy
Price Target: $3.5 → $3
Current: $3.34
Upside: -10.18%
Seres Therapeutics
Mar 14, 2025
Maintains: Sell
Price Target: $20 → $15
Current: $17.18
Upside: -12.69%
Alkermes
Feb 14, 2025
Maintains: Buy
Price Target: $30 → $32
Current: $29.41
Upside: +8.81%
BioNTech SE
Nov 8, 2024
Upgrades: Buy
Price Target: $90 → $137
Current: $97.28
Upside: +40.83%
Syndax Pharmaceuticals
Nov 7, 2024
Maintains: Buy
Price Target: $30 → $33
Current: $19.98
Upside: +65.17%
United Therapeutics
Nov 1, 2024
Maintains: Neutral
Price Target: $243 → $302
Current: $479.51
Upside: -37.02%
Royalty Pharma
Aug 14, 2024
Maintains: Buy
Price Target: $50 → $51
Current: $38.67
Upside: +31.89%
Johnson & Johnson
Jul 19, 2024
Maintains: Neutral
Price Target: $160 → $155
Current: $201.62
Upside: -23.12%
Amylyx Pharmaceuticals
Jul 12, 2024
Maintains: Neutral
Price Target: $3 → $4
Current: $13.67
Upside: -70.74%
May 6, 2024
Maintains: Neutral
Price Target: $18 → $20
Current: $7.29
Upside: +174.35%
Apr 11, 2024
Maintains: Neutral
Price Target: $650 → $723
Current: $997.59
Upside: -27.53%
Mar 1, 2024
Maintains: Neutral
Price Target: $29 → $26
Current: $17.76
Upside: +46.40%
Jan 25, 2024
Maintains: Buy
Price Target: $134 → $153
Current: $154.99
Upside: -1.28%
Dec 11, 2023
Upgrades: Buy
Price Target: $173
Current: $223.12
Upside: -22.46%
Nov 9, 2023
Upgrades: Outperform
Price Target: n/a
Current: $57.28
Upside: -
Oct 30, 2023
Maintains: Buy
Price Target: $81 → $69
Current: $51.67
Upside: +33.54%
Mar 3, 2023
Maintains: Neutral
Price Target: $15 → $13
Current: $21.00
Upside: -38.10%
Mar 1, 2023
Maintains: Neutral
Price Target: $20 → $23
Current: $80.06
Upside: -71.27%
Dec 19, 2022
Initiates: Buy
Price Target: $50
Current: $8.80
Upside: +468.18%
Dec 16, 2022
Maintains: Buy
Price Target: $40 → $52
Current: $94.30
Upside: -44.86%
Dec 13, 2022
Upgrades: Buy
Price Target: $47 → $60
Current: $25.77
Upside: +132.83%
Nov 8, 2022
Maintains: Neutral
Price Target: $13 → $18
Current: $11.04
Upside: +63.04%
Sep 7, 2021
Initiates: Buy
Price Target: $17
Current: $9.60
Upside: +77.08%
Jul 14, 2020
Initiates: Outperform
Price Target: n/a
Current: $2.15
Upside: -
Feb 10, 2020
Initiates: Outperform
Price Target: n/a
Current: $5.88
Upside: -
Jan 24, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $5.40
Upside: -